Wave announces details of its upcoming DMD trial

Published Date
Beatriz Bustillo Ramirez
Orange box stating: Breaking news research

Wave Life Sciences has shared details of its upcoming Phase II/III clinical trial testing suvodirsen in boys with DMD. Suvodirsen is an exon-skipping drug that targets exon 51 within the dystrophin gene. The study, named DYSTANCE 51, will start in July 2019 and enrol boys who are between 5 and 12 years of age. Participants will receive suvodirsen or placebo once a week for 48 weeks.

For further information, please read Wave’s press release.

If you have any questions about this news story or any other DMD research, please contact the MDUK Research Line on 020 7803 4813 or email research@musculardystrophyuk.org.

Keep in touch